Cell Therapy for Motor Neuron Disease/Amyotrophic Lateral Sclerosis

Neurogen Brain and Spine Institute

Status and phase: Withdrawn; Phase 1

Conditions: Amyotrophic Lateral Sclerosis

Treatments: Biological: Stem Cell

Study type: Interventional

Funder types: Other

Identifiers

NCT02242071

NGBSI-10

Details and patient eligibility

About

The effect of autologous bone marrow mononuclear cells on Motor Neuron Disease/Amyotrophic Lateral Sclerosis patients.

Sex: All

Ages: 18 to 80 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with the diagnosis of definite Motor Neuron Disease/amyotrophic lateral sclerosis.
• Age 18-80 years

Exclusion criteria

• HIV/HBV/HCV
• Malignancies
• Bleeding tendencies
• Pneumonia
• Renal failure
• Severe liver dysfunction
• Severe anemia [hb < 8]
• Any bone marrow disorder
• Space occupying lesion in brain
• Pregnancy and lactation
• Other acute medical conditions/infections such as respiratory infection and pyrexia
• left ventricular ejection fraction < 25%
• Patient on artificial ventilatory support

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

0 participants in 1 patient group

Stem Cell

Experimental group

Description:

bone marrow mononuclear cell transplantation

Treatment:

Biological: Stem Cell